Literature DB >> 21547706

Super-selection of a subgroup of hepatocellular carcinoma patients at minimal risk of recurrence for liver transplantation.

Shin Hwang1, Chul-Soo Ahn, Ki-Hun Kim, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Young-Dong Yu, Pyoung-Jae Park, Young-Il Choi, Kyoung-Won Kim, Young-Suk Lim, Han Chu Lee, Eun-Sil Yu, Sung-Gyu Lee.   

Abstract

BACKGROUND: A majority of patients with hepatocellular carcinoma (HCC) undergoing liver transplantation (LT) meet the Milan criteria, but these are still regarded as the narrowest criteria for transplantation. Prognostic analysis of incidentally detected HCC after LT suggests that a subgroup of HCC patients is at very low risk of recurrence. To determine the criteria defining this super-selection group, we retrospectively analyzed survival data of 593 adult living-donor LT recipients with HCC in the explanted liver DISCUSSION: Tumor features of incidental HCC in 38 patients not showing recurrence were analyzed. Of these patients, 34 (89.5%) each had ≤2 tumors and tumors ≤2.0 cm in size. Applying these criteria to 555 patients with pretransplant known HCC (pkHCC) allowed us to identify 79 patients with untreated pkHCCs ≤2.0 cm in size. To date, only two of these patients have shown recurrence, making the conditions for super-selection the presence of tumors ≤2.0 cm in size, ≤2 tumors, alpha-fetoprotein ≤200 ng/mL, and no pretransplant treatment. In 87 patients satisfying these criteria, the 10-year recurrence and survival rates were 1.3% and 92.1%, respectively. After excluding patients meeting these criteria, the 5-year recurrence rates in patients satisfying the Milan, University of California at San Francisco, and Asan criteria were increased by 2.9-4.0%. In conclusion, this super-selection or super-Milan category may be used for validation assessment of various indication criteria and for the development of cost-effective post-transplantation HCC surveillance protocols. Further studies should be followed for deceased-donor LT and patients who have undergone pretransplant treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21547706     DOI: 10.1007/s11605-011-1467-0

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  48 in total

1.  The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients.

Authors:  Sung Hoon Yang; Kyung-Suk Suh; Hae Won Lee; Eung-Ho Cho; Jai Young Cho; Yong Beom Cho; Nam-Joon Yi; Kuhn Uk Lee
Journal:  Liver Transpl       Date:  2006-11       Impact factor: 5.799

2.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

3.  Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study.

Authors:  Jessica Y Leung; Andrew X Zhu; Fredric D Gordon; Daniel S Pratt; Abigail Mithoefer; Kathryn Garrigan; Adam Terella; Martin Hertl; A Benedict Cosimi; Raymond T Chung
Journal:  Liver Transpl       Date:  2004-11       Impact factor: 5.799

4.  A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma.

Authors:  Sung Hoon Yang; Kyung-Suk Suh; Hae Won Lee; Eung-Ho Cho; Jai Young Cho; Yong Beom Cho; In Hwan Kim; Nam-Joon Yi; Kuhn Uk Lee
Journal:  Surgery       Date:  2007-03-23       Impact factor: 3.982

5.  Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation.

Authors:  William C Chapman; M B Majella Doyle; Jourdan E Stuart; Neeta Vachharajani; Jeffrey S Crippin; Christopher D Anderson; Jeffrey A Lowell; Surendra Shenoy; Michael D Darcy; Daniel B Brown
Journal:  Ann Surg       Date:  2008-10       Impact factor: 12.969

6.  Tumour size and differentiation in predicting recurrence of hepatocellular carcinoma after liver transplantation: external validation of a new prognostic score.

Authors:  L Marelli; A Grasso; M Pleguezuelo; H Martines; R Stigliano; A P Dhillon; D Patch; B R Davidson; D Sharma; K Rolles; A K Burroughs
Journal:  Ann Surg Oncol       Date:  2008-09-06       Impact factor: 5.344

7.  Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria.

Authors:  Francesco D'Amico; Myron Schwartz; Alessandro Vitale; Parissa Tabrizian; Sasan Roayaie; Swan Thung; Maria Guido; Juan del Rio Martin; Thomas Schiano; Umberto Cillo
Journal:  Liver Transpl       Date:  2009-10       Impact factor: 5.799

8.  Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database.

Authors:  Christian Toso; Sonal Asthana; David L Bigam; A M James Shapiro; Norman M Kneteman
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

9.  Diagnostic performance of multidetector row computed tomography, superparamagnetic iron oxide-enhanced magnetic resonance imaging, and dual-contrast magnetic resonance imaging in predicting the appropriateness of a transplant recipient based on milan criteria: correlation with histopathological findings.

Authors:  Dong Ho Lee; Se Hyung Kim; Jeong Min Lee; Hee Sun Park; Jae Young Lee; Nam-Joon Yi; Kyung-Suk Suh; Ja June Jang; Joon Koo Han; Byung Ihn Choi
Journal:  Invest Radiol       Date:  2009-06       Impact factor: 6.016

10.  18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients.

Authors:  A Kornberg; M Freesmeyer; E Bärthel; K Jandt; K Katenkamp; J Steenbeck; A Sappler; O Habrecht; D Gottschild; U Settmacher
Journal:  Am J Transplant       Date:  2009-02-03       Impact factor: 8.086

View more
  6 in total

1.  Clinical validity of Metroticket calculator in transplant patients undergoing prior chemoembolization for hepatocellular carcinoma.

Authors:  Hyung-Don Kim; Gi-Won Song; Ju Hyun Shim; Seungbong Han; Jihyun An; Deok-Bog Moon; Kang Mo Kim; Young-Suk Lim; Gi-Young Ko; Shin Hwang; Han Chu Lee; Eunsil Yu; Kyu-Bo Sung; Sung-Gyu Lee
Journal:  Hepatol Int       Date:  2017-01-31       Impact factor: 6.047

2.  Resection of pulmonary metastases from hepatocellular carcinoma following liver transplantation.

Authors:  Shin Hwang; Yong-Hee Kim; Dong Kwan Kim; Chul-Soo Ahn; Deog-Bok Moon; Ki-Hun Kim; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Hyeong Ryul Kim; Gil-Chun Park; Jeong-Man Namgoong; Sam-Youl Yoon; Sung-Won Jung; Seung Il Park; Sung-Gyu Lee
Journal:  World J Surg       Date:  2012-07       Impact factor: 3.352

3.  Changes in the indications for living donor liver transplantation: single-institution experience of 3,145 cases over 10 years.

Authors:  Sang-Hyun Kang; Shin Hwang; Chul-Soo Ahn; Ki-Hun Kim; Deok-Bog Moon; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Gil-Chun Park; Jung-Man Namgoong; Young-In Yoon; Hui-Dong Cho; Jae-Hyun Kwon; Yong-Kyu Chung; Jin-Uk Choi; Sung-Gyu Lee
Journal:  Korean J Transplant       Date:  2020-03-31

4.  Late recurrence of hepatocellular carcinoma after liver transplantation.

Authors:  Julia A Zhang; Sandi A Kwee; Linda L Wong
Journal:  Hepatoma Res       Date:  2017-04-10

5.  α-fetoprotein-to-total tumor volume ratio predicts post-operative tumor recurrence in hepatocellular carcinoma.

Authors:  Yun-Hsuan Lee; Chia-Yang Hsu; Yi-Hsiang Huang; Chien-Wei Su; Han-Chieh Lin; Cheng-Yuan Hsia; Teh-Ia Huo
Journal:  J Gastrointest Surg       Date:  2012-11-28       Impact factor: 3.452

6.  Pretransplant Hepatic Malignancy Increases Risk of De Novo Malignancy after Liver Transplantation.

Authors:  Gil Chun Park; Shin Hwang; Chul Soo Ahn; Ki Hun Kim; Deok Bog Moon; Tae Yong Ha; Gi Won Song; Dong Hwan Jung; Young In Yoon; Hui Dong Cho; Jae Hyun Kwon; Yong Kyu Chung; Sang Hyun Kang; Jin Uk Choi; I Ji Jung; Sung Gyu Lee
Journal:  J Korean Med Sci       Date:  2020-03-23       Impact factor: 2.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.